226 related articles for article (PubMed ID: 24212829)
1. Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects.
Mizejewski GJ
Cancers (Basel); 2011 Jun; 3(2):2709-33. PubMed ID: 24212829
[TBL] [Abstract][Full Text] [Related]
2. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent.
Mizejewski GJ
Cancer Biother Radiopharm; 2007 Feb; 22(1):73-98. PubMed ID: 17627416
[TBL] [Abstract][Full Text] [Related]
3. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects.
Mizejewskia GJ; Butterstein G
Curr Protein Pept Sci; 2006 Feb; 7(1):73-100. PubMed ID: 16472170
[TBL] [Abstract][Full Text] [Related]
4. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis.
Muehlemann M; Miller KD; Dauphinee M; Mizejewski GJ
Cancer Metastasis Rev; 2005 Sep; 24(3):441-67. PubMed ID: 16258731
[TBL] [Abstract][Full Text] [Related]
5. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics.
Mizejewski GJ; MacColl R
Mol Cancer Ther; 2003 Nov; 2(11):1243-55. PubMed ID: 14617798
[TBL] [Abstract][Full Text] [Related]
6. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis.
Mizejewski GJ; Muehlemann M; Dauphinee M
Chemotherapy; 2006; 52(2):83-90. PubMed ID: 16498241
[TBL] [Abstract][Full Text] [Related]
7. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors.
Mizejewski G; Smith G; Butterstein G
Cell Biol Int; 2004; 28(12):913-33. PubMed ID: 15566961
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center Collaborative Study.
Mizejewski GJ; Mirowski M; Garnuszek P; Maurin M; Cohen BD; Poiesz BJ; Posypanova GA; Makarov VA; Severin ES; Severin SE
J Drug Target; 2010 Sep; 18(8):575-88. PubMed ID: 20151941
[TBL] [Abstract][Full Text] [Related]
9. The effects of growth inhibitory peptide on follicular thyroid cancer cell growth, migration, and invasion.
Hua SC; Chen SY; Lu CH; Kao YT; Yu HI; Chen PT; Lee YR; Chang TC
Tumori; 2010; 96(3):448-51. PubMed ID: 20845807
[TBL] [Abstract][Full Text] [Related]
10. Alpha-fetoprotein-derived antiestrotrophic octapeptide.
Mesfin FB; Bennett JA; Jacobson HI; Zhu S; Andersen TT
Biochim Biophys Acta; 2000 Apr; 1501(1):33-43. PubMed ID: 10727847
[TBL] [Abstract][Full Text] [Related]
11. AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats.
Tower AM; Trinward A; Lee K; Joseph L; Jacobson HI; Bennett JA; Andersen TT
Oncol Rep; 2009 Jul; 22(1):49-56. PubMed ID: 19513504
[TBL] [Abstract][Full Text] [Related]
12. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP.
Parikh RR; Gildener-Leapman N; Narendran A; Lin HY; Lemanski N; Bennett JA; Jacobson HI; Andersen TT
Clin Cancer Res; 2005 Dec; 11(23):8512-20. PubMed ID: 16322315
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.
Friedrichsen BN; Neubauer N; Lee YC; Gram VK; Blume N; Petersen JS; Nielsen JH; Møldrup A
J Endocrinol; 2006 Mar; 188(3):481-92. PubMed ID: 16522728
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
15. AFP peptide (AFPep) as a potential growth factor for prostate cancer.
Zhu Z; West GR; Wang DC; Collins AB; Xiao H; Bai Q; Mesfin FB; Wakefield MR; Fang Y
Med Oncol; 2021 Nov; 39(1):2. PubMed ID: 34739644
[TBL] [Abstract][Full Text] [Related]
16. The isolation and sequencing of human gastric inhibitory peptide (GIP).
Moody AJ; Thim L; Valverde I
FEBS Lett; 1984 Jul; 172(2):142-8. PubMed ID: 6745415
[TBL] [Abstract][Full Text] [Related]
17. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
18. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1.
Ball KL; Lain S; Fâhraeus R; Smythe C; Lane DP
Curr Biol; 1997 Jan; 7(1):71-80. PubMed ID: 8999999
[TBL] [Abstract][Full Text] [Related]
19. RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion.
Sommer CA; Mostoslavsky G
Mol Endocrinol; 2014 Nov; 28(11):1855-65. PubMed ID: 25268051
[TBL] [Abstract][Full Text] [Related]
20. The alpha-fetoprotein third domain receptor binding fragment: in search of scavenger and associated receptor targets.
Mizejewski GJ
J Drug Target; 2015; 23(6):538-51. PubMed ID: 25766080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
